

**Europe Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation, and Intravesical Instillation) and Disease Type (Idiopathic Overactive Bladder and Neurogenic Bladder)**

Market Report | 2023-01-13 | 153 pages | The Insight Partners

**AVAILABLE LICENSES:**

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

**Report description:**

The Europe overactive bladder treatment market is expected to grow from US\$ 1,111.05 million in 2022 to US\$ 1,318.55 million by 2028; it is estimated to grow at a CAGR of 2.9% from 2022 to 2028.

Growing Incidence of Urinary Tract Infections Fuels Europe Overactive Bladder Treatment Market Growth

Urinary tract infection (UTI) may lead to increased activity in the bladder wall muscles, causing symptoms similar to an overactive bladder. The bacteria causing UTIs reside in the lining of urothelial cells, and they attack the host body when their innate immunity is low. Individuals with recurrent UTIs are found to have voiding dysfunction and detrusor overactivity, and these functional abnormalities can further damage the integrity of the urothelial barrier. UTI is the eighth and fifth most common reason for ambulatory clinic visits and emergency department visits, respectively, in the country. Moreover, as per the National Institute for Health and Care Excellence organization, UTIs are among the most common hospital-acquired infections in the UK, accounting for ~23% of all infections. According to the BMC Family Practice, UTI consultations accounted for ~2% of ED visits in the Netherlands in 2019. Similarly, in France, ~4-6 million people suffer from UTI each year. Thus, the increasing incidence of UTIs, coupled with the association of UTIs with overactive bladder, is one of the prominent factors contributing to the Europe overactive bladder treatment market growth.

Europe Overactive Bladder Treatment Market Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

The Europe overactive bladder treatment market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global overactive bladder treatment market and is estimated to register a substantial CAGR over the forecast period. The growing demand for overactive bladder treatment due to the presence of the geriatric population is driving the market growth in Europe. Further, the prevalence of neurological diseases and diabetes hampering urinary tract functions is likely to create opportunities for the growth of overactive bladder treatment in the coming years. According to the UK Parliament's data, approximately one-fifth of the total UK population was aged 65 and above in 2019. Besides, the number of people in this age group increased by 23% from 2009 to 2019, while the total UK population increased by only 7% during the same period. Diabetes UK states that ~3.9 million people were diagnosed with diabetes in 2019, and it reached 4.7 million in 2021. The rising prevalence of diabetes and the growing elderly population in the UK lead to surging cases of overactive bladder condition, thereby stroking the demand for its treatment.

#### Europe Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US\$ Million)

#### Europe Overactive Bladder Treatment Market Segmentation

The Europe overactive bladder treatment market is segmented into pharmacotherapy, disease type, and country.

The Europe overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.

Based on pharmacotherapy, the market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the market in 2022. Based on disease type, the Europe overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022. Based on country, the Europe overactive bladder treatment market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The UK dominated the market in 2022. AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the overactive bladder treatment market in Europe.

#### Table of Contents:

##### TABLE OF CONTENTS

- 1. Introduction
  - 1.1 Study Scope
  - 1.2 The Insight Partners Research Report Guidance
  - 1.3 Market Segmentation
    - 1.3.1 Europe Overactive Bladder Treatment Market- By Pharmacotherapy
    - 1.3.2 Europe Overactive Bladder Treatment Market- By Disease Type
    - 1.3.3 Europe Overactive Bladder Treatment Market - By Country
- 2. Europe Overactive Bladder Treatment Market - Key Takeaways
- 3. Research Methodology
  - 3.1 Coverage
  - 3.2 Secondary Research
  - 3.3 Primary Research
- 4. Europe Overactive Bladder Treatment Market - Market Landscape
  - 4.1 Overview
  - 4.2 Europe PEST Analysis
  - 4.3 Expert Opinion

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## 5. Europe Overactive Bladder Treatment Market - Key Market Dynamics

### 5.1 Market Drivers

#### 5.1.1 Increase in Prevalence of Urinary Incontinence

#### 5.1.2 Growing Incidence of Urinary Tract Infections

### 5.2 Key Market Restraints

#### 5.2.1 Recalls of Therapeutic Drugs

### 5.3 Key Market Opportunities

#### 5.3.1 Increasing Number of Mergers and Acquisitions

### 5.4 Future Trends

#### 5.4.1 Robust Pipeline of Drugs and Successive Launch of Novel Therapies

### 5.5 Impact analysis

## 6. Europe Overactive Bladder Treatment Market - Europe Analysis

### 6.1 Europe Overactive Bladder Treatment Market Revenue Forecast and Analysis

## 7. Europe Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Pharmacotherapy

### 7.1 Overview

#### 7.2 Europe Overactive Bladder Treatment Market, By Pharmacotherapy 2021 & 2028 (%)

### 7.3 Mirabegron

#### 7.3.1 Overview

#### 7.3.2 Mirabegron: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)

### 7.4 Botox

#### 7.4.1 Overview

#### 7.4.2 Botox: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)

### 7.5 Neurostimulation

#### 7.5.1 Overview

#### 7.5.2 Neurostimulation: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Mn)

#### 7.5.3 Transcutaneous Sacral Nerve Stimulation

##### 7.5.3.1 Overview

##### 7.5.3.2 Transcutaneous Sacral Nerve Stimulation: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Mn)

#### 7.5.4 Transcutaneous Tibial Nerve Stimulation

##### 7.5.4.1 Overview

##### 7.5.4.2 Transcutaneous Tibial Nerve Stimulation: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Mn)

#### 7.5.5 Percutaneous Posterior Tibial Nerve Stimulation

##### 7.5.5.1 Overview

##### 7.5.5.2 Percutaneous Posterior Tibial Nerve Stimulation: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Mn)

#### 7.5.6 Others

##### 7.5.6.1 Overview

##### 7.5.6.2 Others: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Mn)

### 7.6 Anticholinergics

#### 7.6.1 Overview

#### 7.6.2 Anticholinergics: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)

#### 7.6.3 Solifenacin

##### 7.6.3.1 Overview

##### 7.6.3.2 Solifenacin: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)

#### 7.6.4 Oxybutynin

##### 7.6.4.1 Overview

##### 7.6.4.2 Oxybutynin: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 7.6.5 Fesoterodine
  - 7.6.5.1 Overview
  - 7.6.5.2 Fesoterodine: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)
- 7.6.6 Darifenacin
  - 7.6.6.1 Overview
  - 7.6.6.2 Darifenacin: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)
- 7.6.7 Tolterodine
  - 7.6.7.1 Overview
  - 7.6.7.2 Tolterodine: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)
- 7.6.8 Trosipium
  - 7.6.8.1 Overview
  - 7.6.8.2 Trosipium: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)
- 7.6.9 Other Anticholinergics
  - 7.6.9.1 Overview
  - 7.6.9.2 Other Anticholinergics: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)
- 7.7 Intravesical Instillation
  - 7.7.1 Overview
  - 7.7.2 Intravesical Instillation: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Mn)
- 8. Europe Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Disease Type
  - 8.1 Overview
  - 8.2 Europe Overactive Bladder Treatment Market, By Disease Type 2021 & 2028 (%)
  - 8.3 Idiopathic Overactive Bladder
    - 8.3.1 Overview
    - 8.3.2 Idiopathic: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Mn)
  - 8.4 Neurogenic Overactive Bladder
    - 8.4.1 Overview
    - 8.4.2 Neurogenic: Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Mn)
- 9. Overactive Bladder Treatment Market Revenue and Forecasts to 2028 - Country Analysis
  - 9.1 Overview
    - 9.1.2 Europe: Overactive Bladder Treatment Market, by Country, 2021 & 2028 (%)
      - 9.1.2.1 UK: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US\$ Million)
        - 9.1.2.1.1 UK: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US\$ Million)
        - 9.1.2.1.2 UK: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US\$ Million)
          - 9.1.2.1.2.1 UK: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US\$ Million)
          - 9.1.2.1.2.2 UK: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US\$ Million)
        - 9.1.2.1.3 UK: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US\$ Million)
      - 9.1.2.2 Germany: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US\$ Million)
        - 9.1.2.2.1 Germany: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US\$ Million)
        - 9.1.2.2.2 Germany: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US\$ Million)
          - 9.1.2.2.2.1 Germany: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US\$ Million)
          - 9.1.2.2.2.2 Germany: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US\$ Million)
        - 9.1.2.2.3 Germany: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US\$ Million)
      - 9.1.2.3 France: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US\$ Million)
        - 9.1.2.3.1 France: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US\$ Million)
        - 9.1.2.3.2 France: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US\$ Million)
          - 9.1.2.3.2.1 France: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US\$ Million)
          - 9.1.2.3.2.2 France: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.1.2.3.3 France: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US\$ Million)
- 9.1.2.4 Italy: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US\$ Million)
  - 9.1.2.4.1 Italy: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US\$ Million)
  - 9.1.2.4.2 Italy: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US\$ Million)
    - 9.1.2.4.2.1 Italy: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US\$ Million)
    - 9.1.2.4.2.2 Italy: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US\$ Million)
  - 9.1.2.4.3 Italy: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US\$ Million)
- 9.1.2.5 Spain: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US\$ Million)
  - 9.1.2.5.1 Spain: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US\$ Million)
  - 9.1.2.5.2 Spain: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US\$ Million)
    - 9.1.2.5.2.1 Spain: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US\$ Million)
    - 9.1.2.5.2.2 Spain: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US\$ Million)
  - 9.1.2.5.3 Spain: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US\$ Million)
- 9.1.2.6 Rest of Europe: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US\$ Million)
  - 9.1.2.6.1 Rest of Europe: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US\$ Million)
  - 9.1.2.6.2 Rest of Europe: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US\$ Million)
    - 9.1.2.6.2.1 Rest of Europe: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US\$ Million)
    - 9.1.2.6.2.2 Rest of Europe: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US\$ Million)
  - 9.1.2.6.3 Rest of Europe: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US\$ Million)
- 10. Overactive Bladder Treatment Market- Industry Landscape
  - 10.1 Overview
  - 10.2 Organic Developments
    - 10.2.1 Overview
- 11. Company Profiles
  - 11.1 Alembic Pharmaceuticals Limited
    - 11.1.1 Key Facts
    - 11.1.2 Business Description
    - 11.1.3 Products and Services
    - 11.1.4 Financial Overview
    - 11.1.5 SWOT Analysis
    - 11.1.6 Key Developments
  - 11.2 Astellas Pharma Inc
    - 11.2.1 Key Facts
    - 11.2.2 Business Description
    - 11.2.3 Products and Services
    - 11.2.4 Financial Overview
    - 11.2.5 SWOT Analysis
    - 11.2.6 Key Developments
  - 11.3 AbbVie Inc
    - 11.3.1 Key Facts
    - 11.3.2 Business Description
    - 11.3.3 Products and Services
    - 11.3.4 Financial Overview
    - 11.3.5 SWOT Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.3.6 Key Developments
- 11.4 Teva Pharmaceutical Industries Ltd
  - 11.4.1 Key Facts
  - 11.4.2 Business Description
  - 11.4.3 Products and Services
  - 11.4.4 Financial Overview
  - 11.4.5 SWOT Analysis
  - 11.4.6 Key Developments
- 11.5 Endo Pharmaceuticals Inc.
  - 11.5.1 Key Facts
  - 11.5.2 Business Description
  - 11.5.3 Products and Services
  - 11.5.4 Financial Overview
  - 11.5.5 SWOT Analysis
  - 11.5.6 Key Developments
- 11.6 Hisamitsu Pharmaceutical Co., Inc.
  - 11.6.1 Key Facts
  - 11.6.2 Business Description
  - 11.6.3 Products and Services
  - 11.6.4 Financial Overview
  - 11.6.5 SWOT Analysis
  - 11.6.6 Key Developments
- 11.7 Medtronic Plc
  - 11.7.1 Key Facts
  - 11.7.2 Business Description
  - 11.7.3 Products and Services
  - 11.7.4 Financial Overview
  - 11.7.5 SWOT Analysis
  - 11.7.6 Key Developments
- 11.8 Pfizer Inc
  - 11.8.1 Key Facts
  - 11.8.2 Business Description
  - 11.8.3 Products and Services
  - 11.8.4 Financial Overview
  - 11.8.5 SWOT Analysis
  - 11.8.6 Key Developments
- 12. Appendix
  - 12.1 About The Insight Partners
  - 12.2 Glossary of Terms

**Europe Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation, and Intravesical Instillation) and Disease Type (Idiopathic Overactive Bladder and Neurogenic Bladder)**

Market Report | 2023-01-13 | 153 pages | The Insight Partners

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User Price	\$3000.00
	Site Price	\$4000.00
	Enterprise Price	\$5000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-07

Signature



**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)